Andrea Botticelli

5.8k total citations
149 papers, 2.2k citations indexed

About

Andrea Botticelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Andrea Botticelli has authored 149 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Oncology, 58 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in Andrea Botticelli's work include Cancer Immunotherapy and Biomarkers (54 papers), Advanced Breast Cancer Therapies (16 papers) and Colorectal Cancer Treatments and Studies (16 papers). Andrea Botticelli is often cited by papers focused on Cancer Immunotherapy and Biomarkers (54 papers), Advanced Breast Cancer Therapies (16 papers) and Colorectal Cancer Treatments and Studies (16 papers). Andrea Botticelli collaborates with scholars based in Italy, United Kingdom and United States. Andrea Botticelli's co-authors include Paolo Marchetti, Marianna Nuti, Ilaria Grazia Zizzari, Federica Mazzuca, Bruna Cerbelli, Michela Roberto, Lidia Strigari, Chiara Napoletano, Maurizio Simmaco and Lorenza Putignani and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Andrea Botticelli

132 papers receiving 2.2k citations

Peers

Countries citing papers authored by Andrea Botticelli

Since Specialization

Citations

This map shows the geographic impact of Andrea Botticelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Botticelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Botticelli more than expected).

Fields of papers citing papers by Andrea Botticelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Botticelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Botticelli. The network helps show where Andrea Botticelli may publish in the future.

Co-authorship network of co-authors of Andrea Botticelli

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Botticelli. A scholar is included among the top collaborators of Andrea Botticelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Botticelli. Andrea Botticelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan 2025 ·Cancers ·Alessio Molfino, Giovanni Imbimbo, Simona Pisegna, Simone Scagnoli, (unknown), (unknown), (unknown), Veronica Rizzo, Andrea Botticelli	0
2	CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line 2024 ·Journal of Translational Medicine ·Alain Gelibter, (unknown), Lidia Strigari, Ilaria Grazia Zizzari, (unknown), Fabio Scirocchi, Angelica Pace, (unknown), (unknown), (unknown), Filippo Bellati, Andrea Botticelli, Donatella Paoli, Daniele Santini, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano	7
3	The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients 2024 ·Pathology - Research and Practice ·Andrea Botticelli, Alessio Cirillo, Giulia d’Amati, Cira Di Gioia, Alessandro Corsi, Carlo Della Rocca, Daniele Santini, Raffaella Carletti, Annalinda Pisano, Antonella Polimeni, Marco de Vincentiis, Valentino Valentini, Claudio Di Cristofano, Umberto Romeo, (unknown), Daniela Messineo, Francesca De Felice, Martina Leopizzi, Bruna Cerbelli	2
4	Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis 2024 ·BMC Cancer ·Alessio Cirillo, Daniele Marinelli, Umberto Romeo, Daniela Messineo, Francesca De Felice, Marco de Vincentiis, Valentino Valentini, Silvia Mezi, (unknown), (unknown), (unknown), Bruna Cerbelli, Daniele Santini, Paolo Bossi, Antonella Polimeni, Paolo Marchetti, Andrea Botticelli	4
5	Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab. 2024 ·Journal of Clinical Oncology ·Federica Miglietta, Claudio Vernieri, (unknown), (unknown), Matilde Cacciatore, Andrea Botticelli, Andrea Vingiani, (unknown), Gaia Griguolo, Tommaso Giarratano, (unknown), (unknown), (unknown), Matteo Fassan, Giancarlo Pruneri, Angelo Paolo Dei Tos, Valentina Guarneri, Marleen Kok, Maria Vittoria Dieci	0
6	Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study. 2024 ·Journal of Clinical Oncology ·Andrea Botticelli, Alessandra Fabi, Alessandro Rossi, Roberta Caputo, Simona Pisegna, Francesco Pantano, Giuliana D’Auria, Luisa Carbognin, Palma Fedele, Agnese Fabbri, Claudio Vernieri, Michela Palleschi, G. Ferretti, (unknown), (unknown), (unknown), Ornella Garrone, Diana Giannarelli, Michelino De Laurentiis, Giovanni Scambia	1
7	Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature 2024 ·Cancers ·Marco Filetti, Mario Occhipinti, Alessio Cirillo, Fabio Scirocchi, Alessio Ugolini, Raffaele Giusti, Pasquale Lombardi, Gennaro Daniele, Andrea Botticelli, (unknown), Filippo de Braud, Paolo Marchetti, Marianna Nuti, Elisabetta Ferretti, Lorenzo Farina, Aurelia Rughetti, Manuela Petti	1
8	352TiP Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial 2023 ·Annals of Oncology ·Claudio Vernieri, Francesca Ligorio, (unknown), (unknown), Claudia De Angelis, Monica Iorfida, Andrea Botticelli, Carla Strina, Andrea Vingiani, Leonardo Provenzano, Giulia Bianchi, Secondo Folli, Daniele Generali, Alberto Zambelli, Sabino De Placido, Lucia Del Mastro, (unknown), Giuseppe Capri, Giancarlo Pruneri, Filippo de Braud	2
9	Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients 2023 ·International Journal of Molecular Sciences ·Alessio Cirillo, Ilaria Grazia Zizzari, Andrea Botticelli, Lidia Strigari, Hassan Rahimi, Simone Scagnoli, Fabio Scirocchi, Angelina Pernazza, Angelica Pace, Bruna Cerbelli, Giulia d’Amati, Paolo Marchetti, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano	9
10	A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors 2023 ·Frontiers in Immunology ·Silvia Mezi, Giulia Pomati, Giulia Fiscon, (unknown), Ilaria Grazia Zizzari, Chiara Napoletano, Aurelia Rughetti, Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora, Gaetano Lanzetta, Giulia d’Amati, Marianna Nuti, Daniele Santini, Andrea Botticelli	0
11	Pregnancy-Associated Breast Cancer: A Diagnostic and Therapeutic Challenge 2023 ·Diagnostics ·Francesca Galati, Valentina Magri, (unknown), (unknown), Veronica Rizzo, (unknown), Andrea Botticelli, Federica Pediconi	16
12	Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer 2022 ·Clinical Cancer Research ·Ilaria Grazia Zizzari, (unknown), Andrea Botticelli, Lidia Strigari, Angelina Pernazza, (unknown), Maria Gemma Pignataro, Alessio Ugolini, Fabio Scirocchi, (unknown), Ernesto Rossi, Alain Gelibter, Giovanni Schinzari, Giulia d’Amati, Aurelia Rughetti, Paolo Marchetti, Marianna Nuti, Chiara Napoletano	21
13	Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer 2021 ·Cancers ·Silvia Mezi, Andrea Botticelli, Giulia Pomati, Bruna Cerbelli, Simone Scagnoli, (unknown), Giulia d’Amati, Paolo Marchetti	14
14	Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions 2020 ·Journal of Immunology Research ·Massimo Ralli, Andrea Botticelli, Irene Claudia Visconti, Diletta Angeletti, Marco Fiore, Paolo Marchetti, Alessandro Lambìase, Marco de Vincentiis, Antonio Greco	151
15	Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer 2020 ·Cancers ·Bruna Cerbelli, Simone Scagnoli, Silvia Mezi, Alessandro De Luca, Simona Pisegna, Maria Ida Amabile, Michela Roberto, Lucio Fortunato, Leopoldo Costarelli, Angelina Pernazza, Lidia Strigari, Carlo Della Rocca, Paolo Marchetti, Giulia d’Amati, Andrea Botticelli	18
16	CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer 2019 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Bruna Cerbelli, Andrea Botticelli, Annalinda Pisano, Angelina Pernazza, (unknown), Alessandro De Luca, Paolo A. Ascierto, Maria Gemma Pignataro, Maria Pelullo, Carlo Della Rocca, Paolo Marchetti, Lucio Fortunato, Leopoldo Costarelli, Giulia d’Amati	27
17	Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation? 2019 ·The Breast Journal ·Bruna Cerbelli, Andrea Botticelli, Annalinda Pisano, (unknown), Ludovica De Vincentiis, Angelina Pernazza, Federico Frusone, (unknown), Marco Monti, Lucio Fortunato, Leopoldo Costarelli, Giulia d’Amati	15
18	TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway 2018 ·Cancer Immunology Research ·Ilaria Grazia Zizzari, Chiara Napoletano, Andrea Botticelli, S Caponnetto, Fabio Calabrò, Alain Gelibter, Aurelia Rughetti, Ilary Ruscito, Hassan Rahimi, Ernesto Rossi, Giovanni Schinzari, Paolo Marchetti, Marianna Nuti	51
19	The key role of kynurenine in antiPD-1 failure 2018 ·Open Repository and Bibliography (University of Liège) ·Andrea Botticelli, Bruna Cerbelli, Luana Lionetto, Ilaria Grazia Zizzari, (unknown), Michela Roberto, Concetta Elisa Onesti, Francesca Romana Di Pietro, Chiara Napoletano, Laura Pizzuti, Patrizia Vici, Giulia d’Amati, (unknown), Maurizio Simmaco, (unknown), Paolo Marchetti	1
20	PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy? 2017 ·BioMed Research International ·Bruna Cerbelli, Angelina Pernazza, Andrea Botticelli, Lucio Fortunato, Marco Monti, Paolo Sciattella, (unknown), Federica Mazzuca, (unknown), Giuseppe Naso, Paolo Marchetti, Giulia d’Amati, Leopoldo Costarelli	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact